Exelixis, Inc. (EXEL)
Price:
40.87 USD
( - -0.52 USD)
Your position:
0 USD
ACTION PANEL
ABOUT
Check the
KEY TAKEAWAYS
ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
(REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION
SIMILAR COMPANIES STI SCORE
Similar STI Score
Incyte Corporation
VALUE SCORE:
10
2nd position
ADMA Biologics, Inc.
VALUE SCORE:
11
The best
Genmab A/S
VALUE SCORE:
11
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS PER SHARE
TECHNICAL
DIVIDEND
SIMILAR COMPANIES
DESCRIPTION
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, it is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human mAb against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
NEWS
California Public Employees Retirement System Sells 762,866 Shares of Exelixis, Inc. $EXEL
defenseworld.net
2025-12-12 04:30:56California Public Employees Retirement System decreased its position in Exelixis, Inc. (NASDAQ: EXEL) by 59.2% during the undefined quarter, according to its most recent filing with the SEC. The institutional investor owned 526,649 shares of the biotechnology company's stock after selling 762,866 shares during the period. California Public Employees Retirement System owned about
Exelixis, Inc. (EXEL) Discusses Strategic Approach to Building Next-Generation Oncology Franchises at R&D Day Transcript
seekingalpha.com
2025-12-11 06:12:48Exelixis, Inc. (EXEL) Discusses Strategic Approach to Building Next-Generation Oncology Franchises at R&D Day Transcript
Cresset Asset Management LLC Sells 21,295 Shares of Exelixis, Inc. $EXEL
defenseworld.net
2025-12-11 04:07:23Cresset Asset Management LLC cut its position in shares of Exelixis, Inc. (NASDAQ: EXEL) by 44.0% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 27,140 shares of the biotechnology company's stock after selling 21,295 shares during the quarter. Cresset Asset Management
Why Is Exelixis (EXEL) Up 9% Since Last Earnings Report?
zacks.com
2025-12-04 12:37:46Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock?
Exelixis to Webcast Virtual 2025 Research & Development (R&D) Day on Wednesday, December 10, 2025
businesswire.com
2025-12-03 16:05:00ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that it will webcast its virtual event, Exelixis 2025 R&D Day: Building Next-generation Oncology Franchises, on Wednesday, December 10, 2025, from 1:00 p.m. to 3:30 p.m. EST. During the event, featured speakers will review the progress of Exelixis' R&D activities and outline the company's strategy to advance future oncology franchises. These efforts underscore Exelixis' continued focus on raising standards o.
Arrowstreet Capital Limited Partnership Grows Holdings in Exelixis, Inc. $EXEL
defenseworld.net
2025-12-03 03:20:56Arrowstreet Capital Limited Partnership lifted its position in shares of Exelixis, Inc. (NASDAQ: EXEL) by 42.9% during the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 5,262,643 shares of the biotechnology company's stock after buying an additional 1,580,567 shares during the quarter. Arrowstreet
2 Under-the-Radar Stocks to Buy Heading Into 2026
fool.com
2025-12-01 20:06:00Axsome Therapeutics boasts a deep late-stage pipeline with billions in potential revenue opportunity. Exelixis' core franchise remains strong while it develops promising new medicines.
Capital Fund Management S.A. Acquires 17,673 Shares of Exelixis, Inc. $EXEL
defenseworld.net
2025-11-29 04:14:45Capital Fund Management S.A. increased its holdings in shares of Exelixis, Inc. (NASDAQ: EXEL) by 6.6% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 283,639 shares of the biotechnology company's stock after buying an additional 17,673
Here's Why Exelixis (EXEL) is a Strong Growth Stock
zacks.com
2025-11-28 10:46:07Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Exelixis (EXEL) International Revenue Trends Deserve Your Attention
zacks.com
2025-11-17 10:16:15Evaluate Exelixis' (EXEL) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
Here's Why Exelixis (EXEL) is a Strong Momentum Stock
zacks.com
2025-11-13 10:51:20The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term
zacks.com
2025-11-11 10:46:16Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Exelixis, Inc. (EXEL) Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference Transcript
seekingalpha.com
2025-11-10 13:41:36Exelixis, Inc. ( EXEL ) Guggenheim Securities 2nd Annual Healthcare Innovation Conference November 10, 2025 10:30 AM EST Company Participants Michael Morrissey - CEO, President & Director Conference Call Participants Michael Schmidt - Guggenheim Securities, LLC, Research Division Presentation Michael Schmidt Guggenheim Securities, LLC, Research Division Welcome to this next fireside chat with Exelixis. With us today, we have Mike Morrissey, President and CEO.
Exelixis: The STELLAR Win Is A Mixed Bag, But Things Look Positive Still
seekingalpha.com
2025-11-06 21:39:00Exelixis is positioned for growth with positive phase 3 data for zanzalintinib in metastatic colorectal cancer, following cabozantinib's success. STELLAR-303 results show modest survival benefit but introduce the first immunotherapy approach in refractory mCRC, despite notable toxicity concerns. EXEL's pipeline strength is buoyed by zanzalintinib, but real-world adoption and broader success remain uncertain due to tolerability and trial design limitations.
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November
businesswire.com
2025-11-06 16:05:00ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in November: Guggenheim 2nd Annual Healthcare Innovation Conference: Exelixis is scheduled to present at 10:30 a.m. ET / 7:30 a.m. PT on Monday, November 10 in Boston. Stifel 2025 Healthcare Conference: Exelixis is scheduled to present at 8:40 a.m. ET / 5:40 a.m. PT on Tuesday, November 11 in New York City. To access the.
EXEL Tops Q3 Earnings Estimates, Cabometyx Fuels Product Sales
zacks.com
2025-11-05 11:56:17Exelixis posts strong Q3 results with earnings and revenue beats, boosted by Cabometyx sales, and narrows 2025 guidance.
No data to display
California Public Employees Retirement System Sells 762,866 Shares of Exelixis, Inc. $EXEL
defenseworld.net
2025-12-12 04:30:56California Public Employees Retirement System decreased its position in Exelixis, Inc. (NASDAQ: EXEL) by 59.2% during the undefined quarter, according to its most recent filing with the SEC. The institutional investor owned 526,649 shares of the biotechnology company's stock after selling 762,866 shares during the period. California Public Employees Retirement System owned about
Exelixis, Inc. (EXEL) Discusses Strategic Approach to Building Next-Generation Oncology Franchises at R&D Day Transcript
seekingalpha.com
2025-12-11 06:12:48Exelixis, Inc. (EXEL) Discusses Strategic Approach to Building Next-Generation Oncology Franchises at R&D Day Transcript
Cresset Asset Management LLC Sells 21,295 Shares of Exelixis, Inc. $EXEL
defenseworld.net
2025-12-11 04:07:23Cresset Asset Management LLC cut its position in shares of Exelixis, Inc. (NASDAQ: EXEL) by 44.0% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 27,140 shares of the biotechnology company's stock after selling 21,295 shares during the quarter. Cresset Asset Management
Why Is Exelixis (EXEL) Up 9% Since Last Earnings Report?
zacks.com
2025-12-04 12:37:46Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock?
Exelixis to Webcast Virtual 2025 Research & Development (R&D) Day on Wednesday, December 10, 2025
businesswire.com
2025-12-03 16:05:00ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that it will webcast its virtual event, Exelixis 2025 R&D Day: Building Next-generation Oncology Franchises, on Wednesday, December 10, 2025, from 1:00 p.m. to 3:30 p.m. EST. During the event, featured speakers will review the progress of Exelixis' R&D activities and outline the company's strategy to advance future oncology franchises. These efforts underscore Exelixis' continued focus on raising standards o.
Arrowstreet Capital Limited Partnership Grows Holdings in Exelixis, Inc. $EXEL
defenseworld.net
2025-12-03 03:20:56Arrowstreet Capital Limited Partnership lifted its position in shares of Exelixis, Inc. (NASDAQ: EXEL) by 42.9% during the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 5,262,643 shares of the biotechnology company's stock after buying an additional 1,580,567 shares during the quarter. Arrowstreet
2 Under-the-Radar Stocks to Buy Heading Into 2026
fool.com
2025-12-01 20:06:00Axsome Therapeutics boasts a deep late-stage pipeline with billions in potential revenue opportunity. Exelixis' core franchise remains strong while it develops promising new medicines.
Capital Fund Management S.A. Acquires 17,673 Shares of Exelixis, Inc. $EXEL
defenseworld.net
2025-11-29 04:14:45Capital Fund Management S.A. increased its holdings in shares of Exelixis, Inc. (NASDAQ: EXEL) by 6.6% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 283,639 shares of the biotechnology company's stock after buying an additional 17,673
Here's Why Exelixis (EXEL) is a Strong Growth Stock
zacks.com
2025-11-28 10:46:07Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Exelixis (EXEL) International Revenue Trends Deserve Your Attention
zacks.com
2025-11-17 10:16:15Evaluate Exelixis' (EXEL) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
Here's Why Exelixis (EXEL) is a Strong Momentum Stock
zacks.com
2025-11-13 10:51:20The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term
zacks.com
2025-11-11 10:46:16Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Exelixis, Inc. (EXEL) Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference Transcript
seekingalpha.com
2025-11-10 13:41:36Exelixis, Inc. ( EXEL ) Guggenheim Securities 2nd Annual Healthcare Innovation Conference November 10, 2025 10:30 AM EST Company Participants Michael Morrissey - CEO, President & Director Conference Call Participants Michael Schmidt - Guggenheim Securities, LLC, Research Division Presentation Michael Schmidt Guggenheim Securities, LLC, Research Division Welcome to this next fireside chat with Exelixis. With us today, we have Mike Morrissey, President and CEO.
Exelixis: The STELLAR Win Is A Mixed Bag, But Things Look Positive Still
seekingalpha.com
2025-11-06 21:39:00Exelixis is positioned for growth with positive phase 3 data for zanzalintinib in metastatic colorectal cancer, following cabozantinib's success. STELLAR-303 results show modest survival benefit but introduce the first immunotherapy approach in refractory mCRC, despite notable toxicity concerns. EXEL's pipeline strength is buoyed by zanzalintinib, but real-world adoption and broader success remain uncertain due to tolerability and trial design limitations.
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November
businesswire.com
2025-11-06 16:05:00ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in November: Guggenheim 2nd Annual Healthcare Innovation Conference: Exelixis is scheduled to present at 10:30 a.m. ET / 7:30 a.m. PT on Monday, November 10 in Boston. Stifel 2025 Healthcare Conference: Exelixis is scheduled to present at 8:40 a.m. ET / 5:40 a.m. PT on Tuesday, November 11 in New York City. To access the.
EXEL Tops Q3 Earnings Estimates, Cabometyx Fuels Product Sales
zacks.com
2025-11-05 11:56:17Exelixis posts strong Q3 results with earnings and revenue beats, boosted by Cabometyx sales, and narrows 2025 guidance.